​

Apogee Therapeutics (APGE) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

APGE Stock Forecast

Apogee Therapeutics (APGE) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $90.67, with a high of $109.00 and a low of $60.00. This represents a 18.43% increase from the last price of $76.56.

$25 $42 $59 $76 $93 $110 High: $109 Avg: $90.67 Low: $60 Last Closed Price: $76.56

APGE Stock Rating

Apogee Therapeutics stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 7 Strong Sell Sell Hold Buy Strong Buy

APGE Price Target Upside V Benchmarks

TypeNameUpside
StockApogee Therapeutics18.43%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts133
Avg Price Target$103.00$90.67$90.67
Last Closing Price$76.56$76.56$76.56
Upside/Downside34.54%18.43%18.43%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25111---12
Nov, 25110---11
Oct, 2519---10
Sep, 25-9---9
Aug, 25-9---9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 09, 2025Deutsche Bank$103.00$74.7537.79%34.54%
Nov 03, 2025Craig-Hallum$109.00$56.6392.48%42.37%
Sep 25, 2025RBC Capital$60.00$37.5259.91%-21.63%
May 13, 2024Alex ThompsonStifel Nicolaus$95.00$52.7180.23%24.09%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 09, 2025Deutsche BankBuyinitialise
Nov 03, 2025Craig-HallumBuyinitialise
Sep 25, 2025RBC CapitalOutperforminitialise
Aug 28, 2025CitigroupBuyBuyhold
Jul 11, 2025BTIGBuyBuyhold
Jul 07, 2025CitigroupBuyBuyhold
Mar 03, 2025GuggenheimBuyBuyhold

Financial Forecast

EPS Forecast

$-15 $-12 $-9 $-6 $-3 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.36$-3.30----
Avg Forecast$-3.26$-3.10$-4.32$-5.36$-6.49$-7.03
High Forecast$-1.93$-2.90$-3.38$-3.52$-4.30$-7.03
Low Forecast$-3.85$-3.32$-4.77$-10.81$-12.46$-7.03
Surprise %3.07%6.45%----

Revenue Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast------
High Forecast------
Low Forecast------
Surprise %------

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-83.98M-----
Avg Forecast$-83.98M$-77.65M$-101.84M$-179.14M$-209.56M$-175.70M
High Forecast$-48.25M$-72.39M$-84.47M$-87.90M$-107.52M$-175.70M
Low Forecast$-96.19M$-82.91M$-119.20M$-270.39M$-311.60M$-175.70M
Surprise %------

APGE Forecast FAQ

Is Apogee Therapeutics stock a buy?

Apogee Therapeutics stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Apogee Therapeutics is a favorable investment for most analysts.

What is Apogee Therapeutics's price target?

Apogee Therapeutics's price target, set by 7 Wall Street analysts, averages $90.67 over the next 12 months. The price target range spans from $60 at the low end to $109 at the high end, suggesting a potential 18.43% change from the previous closing price of $76.56.

How does Apogee Therapeutics stock forecast compare to its benchmarks?

Apogee Therapeutics's stock forecast shows a 18.43% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Apogee Therapeutics over the past three months?

  • December 2025: 8.33% Strong Buy, 91.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 9.09% Strong Buy, 90.91% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 10.00% Strong Buy, 90.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Apogee Therapeutics’s EPS forecast?

Apogee Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-4.32, marking a 30.91% increase from the reported $-3.3 in 2024. Estimates for the following years are $-5.36 in 2026, $-6.49 in 2027, and $-7.03 in 2028.

What is Apogee Therapeutics’s revenue forecast?

Apogee Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $0, followed by $0 for 2027, and $0 for 2028.

What is Apogee Therapeutics’s net income forecast?

Apogee Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-102M, representing a 0% decrease from the reported $0 in 2024. Projections indicate $-179M in 2026, $-210M in 2027, and $-176M in 2028.